1) re-restenosis
再再狭窄
2) restenosis
[,ri:sti'nəusis]
再狭窄
1.
Local Application of Paclitaxel for Prevention Restenosis of Vein Graft in Rabbits;
局部应用紫杉醇预防兔移植静脉再狭窄
2.
Experimental study of preventive effect of tetramethylpyrazine-eluting stents on in-stent restenosis;
川芎嗪洗脱支架预防支架内再狭窄的实验研究
3.
Restenosis in patients with symptomatic middle cerebral artery stenosis after stenting:an analysis of influencing factors;
症状性大脑中动脉狭窄患者支架置入术后再狭窄影响因素的分析
3) in-stent restenosis
再狭窄
1.
The in-stent restenosis is one of the main complications in coronary artherosclerotic heart disease patients after PTCA and PCI.
术后靶血管管腔再狭窄是冠状动脉介入治疗术的主要并发症,如何有效预防再狭窄已成为目前介入心脏医学界的主要课题之一。
2.
Several methods about the surface treatment of metallic stents on the in-stent restenosis(ISR) in recent years were reviewed.
综述了近年来针对支架手术中再狭窄而采用的几种金属支架表面改性的方法与可降解医用高分子支架的发展、研究现状,其中包括对目前常用的可降解材料———聚乳酸进行了概述,以及应用有限元方法对可降解支架的支撑力进行的初步探索。
3.
Methods: During the past 17 months ,49 patients for high risk in-stent restenosis undertwent an implan-tation of Cypher and /or Taxus eluting coronary stents.
目的:分析经皮冠状动脉介入治疗(PCI)后再狭窄高危患者应用两种药物洗脱支架的临床疗效。
4) 2.Restenosis
2.再狭窄
5) Percutaneo
再狭窄(restenosis)
6) restenosis rates
再狭窄率
1.
Our study is to observe the difference of cardiovascular event occurrence rates,restenosis rates and in-stent late loss(ISLL) between patients implanted with biodegradable polymer sirolimus-eluting stents and PARTNER stents.
本研究旨在评价新一代的钴基合金可降解涂层雷帕霉素洗脱支架在冠状动脉狭窄病变处理中的安全性和有效性,以及能否进一步降低支架术后再狭窄率及晚期支架内血栓形成率。
补充资料：瓣膜型主动脉口狭窄
瓣膜型主动脉口狭窄
valvular aortic stenosis
见“先天性主动脉瓣膜部狭窄”。
说明：补充资料仅用于学习参考，请勿用于其它任何用途。
参考词条